SIRT1 and fatty liver disease: When administrated to rats fed a high fat diet (HFD), T2 has been reported to prevent body weight gain, liver steatosis, hypercholesterolemia, hypertriglyceridemia and to rapidly (within 6 h) stimulate hepatic fatty acid oxidation via activation of sirtuin 1 (SIRT1), leading to deacetylation of the SIRT1 targets PGC-1α and sterol regulatory-binding proteon-1c with a downstream upregulation of genes involved in mitochondrial biogenesis and a concomitant downregulation of lipogenic genes [127].